



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of:

Brunner, Hans R.

Appl. No.: 10/612,338

Filed: July 3, 2003

For: **Compositions and Methods Involving
the Combination of a Thromboxane
A2 Receptor Antagonist and an Inhibitor
of Cyclooxygenase-2**

Art Unit: to be assigned

Examiner: to be assigned

Atty. Dkt.: 7571/80526

Information Disclosure Statement

Commissioner of Patents
U.S. Patent and Trademark Office
2011 South Clark Place
Customer Window, **MS Missing Parts**
Crystal Plaza Two, Lobby, Room 1B03
Arlington, VA 22202

Sir:

Submitted herewith is a listing of documents known to Applicant and/or his attorney in compliance with the requirements of 37 C.F.R. § 1.56. One of these references was cited in the Search Report for corresponding international application no. PCT/IB03/02633 mailed September 19, 2003, a copy of which is enclosed. Copies of the listed documents are also enclosed.

Applicant does not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the present application. This statement should not be construed as a representation that more material information does not exist or that an exhaustive search of the relevant art has been made.

Consideration of the cited documents and making the same of record in the prosecution of the above-captioned application are respectfully requested.

Applicant does not believe any fee is due for the submission of this Information Disclosure Statement. However, the Commissioner is hereby authorized to charge any fee deficiency to our Deposit Account No. 06-1135 under Order No. 7571/80526.

Respectfully submitted,

FITCH, EVEN, TABIN & FLANNERY

By Michael A. Sanzo

Michael A. Sanzo
Reg. No. 36,912
Attorney for Applicant

Date: November 25, 2003
1801 K Street, N.W., Suite 401L
Washington, DC 20006-1201
Phone: (202) 419-7013

| LIST OF REFERENCES CITED BY APPLICANT <small>(Use separate sheets if necessary)</small> | | | | Atty. Docket No.: 7571/80526 | | Appl No.: 10/612,338 | |
|---|-----------------|--|---------------|--------------------------------|----------|----------------------------|---------------|
| | | | | Applicant(s) Brunner, Hans. R. | | | |
| | | | | Filing Date: July 3, 2003 | | Group: to be assigned | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| Examiner Initial | Document Number | Date | Name | Class | Subclass | Filing Date If Appropriate | |
| | AA 1 | 5,100,889 | Mar. 31, 1992 | Misra, <i>et al.</i> | 514 | 365 | Jun. 18, 1990 |
| | AB 1 | 5,597,848 | Jan. 28, 1997 | Ito, <i>et al.</i> | 514 | 539 | Mar. 16, 1995 |
| | AC 1 | 5,618,941 | Apr. 8, 1997 | Dickinson, <i>et al.</i> | 546 | 249 | Mar. 15, 1995 |
| | AD | | | | | | |
| | AE | | | | | | |
| | AF | | | | | | |
| | AG | | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | |
| | Document Number | Date | Country | Class | Subclass | Translation | |
| | | | | | | Yes | No |
| | AH 1 | WO 01/87343 A2 | Nov. 22, 2001 | WIPO | A61K | 45/06 | |
| | AI | | | | | | |
| | AJ | | | | | | |
| | AK | | | | | | |
| OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | |
| | AL 1 | BOLTEN, "Scientific Rationale for Specific Inhibition of COX-2," <i>J. Rheumatol.</i> 25(51):2-7 (1998). | | | | | |
| | AM1 | GRISWOLD, <i>et al.</i> , "Constitutive Cyclooxygenase (COX-1) and Inducible Cyclooxygenase (COX-2): Rationale for Selective Inhibition and Progress to Date," <i>Med. Res. Rev.</i> 16(2):181-206 (1996). | | | | | |
| | AN 1 | LANE, "Pain Management in Osteoarthritis: The Role of COX-2 Inhibitors," <i>J. Rheumatol.</i> 24(49):20-24 (1997). | | | | | |
| | AO 1 | LIPSKY, <i>et al.</i> , "Outcome of Specific COX-2 Inhibition in Rheumatoid Arthritis," <i>J. Rheumatol.</i> 24(49):9-14 (1997). | | | | | |
| | AP 1 | MUKHERJEE, <i>et al.</i> , "Risk of Cardiovascular Events Associated with Selective COX-2 Inhibitors," <i>JAMA</i> 286:954-959 (2001). | | | | | |
| | AQ 1 | ROSENFELD, <i>et al.</i> , "Ifetroban Sodium: An Effective Tx _{A2} /PGH ₂ Receptor Antagonist," <i>Cardiovascular Drug Rev.</i> 19(2):97-115 (2001). | | | | | |
| | AR 1 | VANE, <i>et al.</i> , "Mechanism of Action of Nonsteroidal Anti-inflammatory Drugs," <i>Am. J. Med.</i> 104(3A):2S-8S (1998). | | | | | |
| | AS | | | | | | |
| Examiner | | | | Date Considered | | | |